Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + FOLFOXIRI Neoadjuvant for pMMR Rectal Cancer
NCT06099951Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2023
- Primary completion
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of serplulimab in rectal cancer, sponsored by Sun Yat-sen University. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06099951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06099951.